Press Release: Nestle: Nestlé completes -2-

accidental exposure to food allergens by desensitizing patients with

defined, precise amounts of key allergens. Aimmune has one FDA-approved

medicine for peanut allergy and other investigational therapies in

development to treat other food allergies. For more information, please

visit www.aimmune.com.

Contacts:

Media:

Christoph Meier Tel.: +41 21 924 2200

mediarelations@nestle.com

https://www.globenewswire.com/Tracker?data=BCeJhydLnKg4om25GRbB2CFzOoOHG0VgsjOHJjF51VyYF_hD7m3hLdPlAa1IxR9pEtryKuOYNspnYZM8P3yrWzimePP6kufMrQ99uktf_4ao2AM4FvkFFnC-FwxiBdKN

Jacquelyn Campo Tel.: +41 78 752 9961

NestleHealthScience.External@nestle.com

https://www.globenewswire.com/Tracker?data=MyN_isJVgvGBZBAmOleAFElPwJOyz2fdIo2HKPiHfr1oq9zbfUJFjStJJ6xQRhUqhf3flTU982uf-KmS3Z_ZTsGZU0E5RVpwjeOoz_dsl1s0Mo2Cc1P3b_RugsLwWgk3ti4hd4DH6SouG21_xjoDfA==

Investors:

Luca Borlini Tel.: +41 21 924 3509

ir@nestle.com

https://www.globenewswire.com/Tracker?data=rucSBVk9W58gloTw1-GcQQbl17hOa22L-htjvkbNlhx6j9P63nlBznMVFAwRbO1hzy2M24Ha8cXswEqKEsSiIg==

(END) Dow Jones Newswires

October 14, 2020 01:15 ET (05:15 GMT)